Browsing Tag
Chiesi Global Rare Diseases
4 posts
What the CHMP’s positive view on lomitapide reveals about the evolving HoFH treatment landscape in children
See how Chiesi Group’s paediatric lomitapide expansion could reshape HoFH treatment access, payer dynamics, and rare disease growth across Europe.
Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.
EMA moves Protalix (PLX) closer to extended dosing approval for Elfabrio in Fabry disease
Protalix BioTherapeutics secures EMA panel backing for monthly Elfabrio dosing in Fabry disease, unlocking a $25M milestone. See what it means for PLX.
Protalix BioTherapeutics receives FDA extension for pegunigalsidase alfa review: What this means for Fabry disease treatment
Protalix BioTherapeutics, a leader in the development of innovative therapies for rare diseases, has announced a significant update…